Ideal candidate for Reslizumab (IL-5 inhibitor) include:
a) Patients with severe allergic asthma and eosinophilic phenotype
b) Patients with cystic fibrosis
c) Patients with non-allergic asthma
d) Patients with chronic obstructive pulmonary disease